Solan Headlines

Thrombocytopenia Market is Projected to Grow During the Forecast Period 2022-2032 – Estimates DelveInsight | Key Companies – Novartis, Zenyaku Kogyo, UCB Biopharma, Principia Biopharma, Baxalta

 Breaking News
  • No posts were found

Thrombocytopenia Market is Projected to Grow During the Forecast Period 2022-2032 – Estimates DelveInsight | Key Companies – Novartis, Zenyaku Kogyo, UCB Biopharma, Principia Biopharma, Baxalta

November 15
00:16 2022
Thrombocytopenia Market is Projected to Grow During the Forecast Period 2022-2032 - Estimates DelveInsight | Key Companies -  Novartis, Zenyaku Kogyo, UCB Biopharma, Principia Biopharma, Baxalta
Thrombocytopenia Treatment Market is expected to experience robust expansion due to the rise in patient pool and availability of products.

DelveInsight’sThrombocytopenia Market report provides a thorough comprehension of the Thrombocytopenia,  historical and forecasted epidemiology, and the Thrombocytopenia market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Thrombocytopenia market report also proffers an analysis of recent Thrombocytopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs. 

 

Some of the vital points from the Thrombocytopenia Market Research Report

  • TThe Thrombocytopenia market size in the 7MM was observed to be USD 4,412 million in 2021 and is expected to grow with a significant CAGR during the forecasted period (2022)
  • In 2021, the total cases of Thrombocytopenia in the 7MM countries were 2,608,095, and these cases are anticipated to increase during the study period (2019-32)
  • Thrombocytopenia Market players such as Sanofi, Rigel Pharmaceuticals, Kissei Pharmaceutical, Sobi, Shionogi & Co., Ltd., Amgen, Novartis, Zenyaku Kogyo, UCB Biopharma, Principia Biopharma, Baxalta, Takeda, Argenx, GC Pharma, Omeros Corporation, Biotest, Millennium Pharmaceuticals, Cellphire, Momenta Pharmaceuticals, ILTOO Pharma, Genosco, and several others are involved in developing Thrombocytopenia therapies.
  • Thrombocytopenia market might experience significant growth due to the expected launch of upcoming therapies such as Rozanolixizumab (UCB7665); Rilzabrutinib (PRN-1008); BAX930; Efgartigimod (ARGX-113); Cablivi (caplacizumab); Tavalisse/Tavlesse (Fostamatinib); Doptelet (Avatrombopag); Nplate (Romiplostim); and Mulpleta (lusutrombopag), and others. 

 

For additional information on Market Impact by Therapies, visit: Thrombocytopenia Therapeutics Market Analysis 

 

Thrombocytopenia is a condition in which the blood has a lower than a normal number of platelets. The condition can be inherited or acquired. Thrombocytopenia causes, sometimes, are not known. The main Thrombocytopenia symptoms include mild-to-severe bleeding. Bleeding can occur inside the body or underneath the skin, or from the skin’s surface. As per DelveInsight’s analysts, the total number of Thrombocytopenia cases in the 7MM was 1,653,934 in 2020. The Thrombocytopenia cases are expected to increase throughout the study period of 20192032 with a decent CAGR.

 

The Thrombocytopenia Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

  • Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP)
  • Prevalent Cases of Immune Thrombocytopenia (ITP)
  • Prevalent Cases of Thrombocytopenia in Chronic Liver Disease
  • Incident Cases of Chemotherapy-induced Thrombocytopenia
  • Number of Cases of Heparin-induced Thrombocytopenia
  • Total Cases of Thrombocytopenia

 

Thrombocytopenia Emerging Therapies Along with Key Players 

Thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved soon. The major key players enumerated below can create a significant positive shift in Thrombocytopenia market size. 

  • Rozanolixizumab (UCB7665): UCB Biopharma
  • Rilzabrutinib (PRN-1008): Principia Biopharma
  • TAK-755 (BAX930/SHP655): Baxalta/Takeda
  • Efgartigimod (ARGX-113): Argenx
  • GC5101B (GC5107A, IV-Globulin SN Inj. 10%): GC Pharma
  • Narsoplimab (OMS721): Omeros Corporation
  • BT-595: Biotest
  • TAK-079: Millennium Pharmaceuticals/Takeda
  • Thrombosomes: Cellphire
  • M254 (Hypersialylated IgG): Momenta Pharmaceuticals
  • BIVV020: Sanofi
  • Interleukin 2: ILTOO Pharma
  • SKI-O-703: Genosco (Subsidiary of Oscotec), And others.

 

Thrombocytopenia Market Drivers 

  • More efficacious therapies 
  • Increase in Thrombocytopenia cases High chances of drug approvals 
  • Increase in patient compliance 
  • Robust pipeline 

 

Thrombocytopenia Market Barriers 

  • Economic burden
  • Low disease awareness and delay in diagnosis
  • Complications associated with current therapies 

 

Scope of the Thrombocytopenia Market Insight 

  • Geography Covered: 7MM – The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
  • Thrombocytopenia Markets Segmentation: By Geographies and By Thrombocytopenia Therapies (Historical and Forecasted, Current and Upcoming) 
  • Leading Thrombocytopenia Market Companies investigating its candidates for Thrombocytopenia:  Sanofi, Rigel Pharmaceuticals, Kissei Pharmaceutical, Sobi, Shionogi & Co., Ltd., Amgen, Novartis, Zenyaku Kogyo, UCB Biopharma, Principia Biopharma, Baxalta, Takeda, Argenx, GC Pharma, Omeros Corporation, Biotest, Millennium Pharmaceuticals, Cellphire, Momenta Pharmaceuticals, ILTOO Pharma, Genosco, and several others.
  • Thrombocytopenia Market Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis, Case Studies, KOL’s Views, Analyst’s View

 

Request for a Webex demo of the report @ Thrombocytopenia Market Size Analysis 

 

Table of Contents 

1

Key Insights on Thrombocytopenia

2

Executive Summary of Thrombocytopenia

3

Thrombocytopenia Market Overview at a Glance

4

Disease Background and Overview: Thrombocytopenia

5

Thrombocytopenia Patient Journey

6

Thrombocytopenia Epidemiology and Patient Population

6.1

United States Epidemiology

6.2

EU5 Countries Epidemiology

6.2.1

Germany

6.2.2

France

6.2.3

Italy

6.2.4

Spain

6.2.5

United Kingdom

6.3

Japan Epidemiology

7

Thrombocytopenia Treatment

8

Thrombocytopenia Unmet Needs

9

Thrombocytopenia Marketed Drugs

9.1

Cablivi (Caplacizumab/ALX-0081): Sanofi (Ablynx)

9.2

Tavalisse (Fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical

9.3

Doptelet (Avatrombopag): Sobi (Dova Pharmaceuticals)

9.4

Mulpleta/Mulpleo (Lusutrombopag): Shionogi & Co., Ltd.

9.5

Nplate (Romiplostim, AMG-531): Amgen

9.6

Promacta (eltrombopag): Novartis

9.7

Rituxan (rituximab): Zenyaku Kogyo

10

Thrombocytopenia Emerging Drugs

10.1

Key Cross Competition

10.2

Rozanolixizumab (UCB7665): UCB Biopharma

10.3

Rilzabrutinib (PRN-1008): Principia Biopharma

10.4

TAK-755 (BAX930/SHP655): Baxalta/Takeda

10.5

Efgartigimod (ARGX-113): Argenx

10.6

GC5101B (GC5107A, IV-Globulin SN Inj. 10%): GC Pharma

10.7

Narsoplimab (OMS721): Omeros Corporation

10.8

BT-595: Biotest

10.9

TAK-079: Millennium Pharmaceuticals/Takeda

10.10

Thrombosomes: Cellphire

10.11

M254 (Hypersialylated IgG): Momenta Pharmaceuticals

10.12

BIVV020: Sanofi

10.13

Interleukin 2: ILTOO Pharma

10.14

SKI-O-703: Genosco (Subsidiary of Oscotec)

11

7MM Thrombocytopenia Market Analysis

12

United States Thrombocytopenia Market Outlook

13

EU-5 Thrombocytopenia Market Outlook

13.1

Germany Market Size

13.2

France Market Size

13.3

Italy Market Size

13.4

Spain Market Size

13.5

United Kingdom Market Size

14

Japan Thrombocytopenia Market Outlook

15

Thrombocytopenia Market Drivers

16

Thrombocytopenia Market Barriers

17

SWOT Analysis

18

Reimbursement and Thrombocytopenia Market Access

19

Appendix

20

DelveInsight Capabilities

21

Disclaimer

22

About DelveInsight

 

Browse detailed TOC with charts, figures, tables @ Thrombocytopenia Market Size Report  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles